Toronto - Delayed Quote CAD

Sernova Corp. (SVA.TO)

0.2250

0.0000

(0.00%)

At close: 3:58:52 PM EST

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to b

GlobeNewswire 21 days ago

SEOVF
Sernova Update on Strategic Initiatives

Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia Renowned Diabetes Expert Dr. Robert Gabbay to Serve as Clinical Advisor Town Hall Call to be Held on December 13; AGM Circular Available on December 6 LONDON, Ontario and BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a

GlobeNewswire last month

SEOVF
Sernova Announces Key New Executive Appointments

LONDON, Ontario and BOSTON - (NewMediaWire) - October 11, 2024 - Experienced leadership team positions company to advance Cell Pouch(TM) bio-hybrid organ programs. - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative med...

NewMediaWire 2 months ago

SEOVF
Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa

LONDON Ontario and BOSTON - (NewMediaWire) - October 03, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic...

NewMediaWire 3 months ago

SEOVF
Sernova Appoints David Paterson Ph.D. to Its Board of Directors

LONDON, Ontario and BOSTON - (NewMediaWire) - September 19, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chron...

NewMediaWire 3 months ago

SEOVF
Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantationHistological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch ChambersSernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and methodsPathology confirmed no evidence of detrimental fibrotic tissue associ

GlobeNewswire 3 months ago

SEOVF
Sernova to Participate in Upcoming H.C. Wainwright Investor Conference

LONDON, Ontario - (NewMediaWire) - September 05, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical- stage company and leader in cell therapeutics, today announced it will be participating in the upcoming H.C. Wainwright 26th An...

NewMediaWire 4 months ago

SEOVF
Sernova Closes $5.2 Million Over-Subscribed Non-Brokered, Private Placement

LONDON, Ontario - (NewMediaWire) - September 04, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it has closed its non-brokered, private placement in the amount over $5.2 million, which includes over-subscription...

NewMediaWire 4 months ago

SEOVF
Lead Investigator for Sernova's Clinical Trial With Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting

LONDON, Ontario and BOSTON, MA - (NewMediaWire) - August 15, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chro...

NewMediaWire 4 months ago

SEOVF
Sernova Corp. Announces Appointment of New Chief Executive Officer

LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer. James Parsons, on behalf of the Board of Dir

GlobeNewswire 4 months ago

SEOVF

ONCY
Jonathan Rigby Appointed as Executive Chairman for Sernova

LONDON, Ontario and BOSTON, MA - (NewMediaWire) - July 15, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chroni...

NewMediaWire 5 months ago

SEOVF
Sernova Announces Additional Patient Insulin Independence and Cohort 2 Enrollment Completion in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes

LONDON, Ontario and BOSTON, MA - (NewMediaWire) - June 25, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company, today announces developments in its Phase I/II clinical trial investigating a novel treat...

NewMediaWire 6 months ago

SEOVF
Sernova Provides Update on Public Offering

LONDON, Ontario and BOSTON, Massachusetts - (NewMediaWire) - June 12, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatme...

NewMediaWire 6 months ago

SEOVF
Sernova Announces Marketed Public Offering of Units

Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) is pleased to announce that it has filed a preliminary short form prospectus in connection with a best efforts marketed public offering (the "Offering") of units of the Company (the "Units"). The Offering is being led by Stifel Nicolaus Canada Inc., as lead agent (the "Lead Agent") and joint bookrunner with Leede Jones Gable Inc., on behalf of a syndicate of agents that includes Ventum Financial Corp., Raymond Jam

CNW Group 7 months ago

SEOVF
Sernova Appoints Jonathan Rigby to its Board of Directors

LONDON, Ontario and BOSTON, MA - (NewMediaWire) - May 28, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic...

NewMediaWire 7 months ago

SEOVF

Performance Overview

Return	SVA.TO	S&P/TSX Composite index
YTD	+2.27%	+0.60%
1-Year	-64.84%	+18.10%
3-Year	-89.39%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sernova Corp. (SVA.TO)

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

Sernova Update on Strategic Initiatives

Sernova Announces Key New Executive Appointments

Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa

Sernova Appoints David Paterson Ph.D. to Its Board of Directors

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova to Participate in Upcoming H.C. Wainwright Investor Conference

Sernova Closes $5.2 Million Over-Subscribed Non-Brokered, Private Placement

Lead Investigator for Sernova's Clinical Trial With Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting

Sernova Corp. Announces Appointment of New Chief Executive Officer

Jonathan Rigby Appointed as Executive Chairman for Sernova

Sernova Announces Additional Patient Insulin Independence and Cohort 2 Enrollment Completion in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes

Sernova Provides Update on Public Offering

Sernova Announces Marketed Public Offering of Units

Sernova Appoints Jonathan Rigby to its Board of Directors

Performance Overview